Recently, Thousand Oaks Biopharmaceuticals Co., Ltd. established partnership with Gensciences Pharmaceuticals (GenSci) to provide CDMO services for the sample production of Phase III clinical trial of the latter’s first-in-class drug of long-acting coagulation factor. The samples were successfully delivered to the United Clinical Research Hospital by a professional pharmaceutical logistics company on September 24, and thus accelerated the clinical research progress. It was the first batch of samples for Phase III clinical trial that Thousand Oaks Biopharmaceuticals Co., Ltd. has delivered to GenSci.
In this project, Thousand Oaks Biopharmaceuticals Co., Ltd., with first-class biopharmaceutical R&D and production service capabilities, provides Phase III clinical trial drug production, process validation, and BLA/NDA filing services for GenSci. It has completed the GMP production of the clinical samples in a very short time on the strength of its comprehensive biopharmaceutical technology platform, and effectively guaranteed the quality of the project, helping GenSci gain competitive advantages more promptly in the market.
Thousand Oaks Biopharmaceuticals Co., Ltd. will make continued efforts and make full use of the powerful alliance to assist GenSci in bringing new drugs to the market with higher quality at a faster speed, thereby further boosting the thriving of biopharmaceutical research and development in China.
The success of this project once again embodied the strength of Thousand Oaks Biopharmaceuticals Co., Ltd. in the biopharmaceutical CDMO field. Boasting Phase III clinical trial and commercial manufacturing capabilities, Thousand Oaks Biopharmaceuticals Co., Ltd., over the past 3 years since its official operation, has fulfilled professional CMC services for about 30 customers including Biothus, provided dozens of customers, including GenSci, with Phase I, Phase II, and Phase III clinical trial drug production services, and won a good reputation. It is bound to be the optimal choice for more and more macromolecular biopharmaceutical partners across China.
Lastly, we wish the clinical research of the project all success and sooner application to patients!